Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation

5 Feb 2025

Abstract excerpt

ABSTRACT: High-dose posttransplantation cyclophosphamide (HD-PTCy), given at 50 mg/kg/day on days +3/+4, is a standard-of-care graft-versus-host disease (GVHD) prophylaxis for allogeneic hematopoietic cell transplantation (HCT). Our murine MHC-haploidentical HCT studies suggested intermediate-dose PTCy produces superior GVHD control compared with HD-PTCy and PTCy is maximally effective on day +4. We conducted a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hematopoietic Stem Cell Transplantation
Share to Immunotherapy and Immune Responses
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39908565
DOI: 10.1182/bloodadvances.2024014879

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantationPMID 39908565Read ↗

Impacts of Posttransplant Cyclophosphamide Dose on Graft-versus-Leukemia Effects via HLA-B Leader in HLA-Haploidentical Peripheral Blood Stem Cell Transplantation.Semantic proximity Read ↗

Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantation.Semantic proximity Read ↗

National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant CyclophosphamideSemantic proximity Read ↗

Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical VariablesSemantic proximity Read ↗

Feasibility of HLA-Haploidentical Hematopoietic Stem Cell Transplantation With Post-Transplantation Cyclophosphamide for Advanced Pediatric MalignanciesSemantic proximity Read ↗

Posttransplant cyclophosphamide in HLA-matched and 1-2 allele mismatched peripheral blood stem cell transplantationSemantic proximity Read ↗

Posttransplant cyclophosphamide in unrelated and related peripheral blood stem cell transplantation from HLA-matched and 1 allele mismatched donor.Semantic proximity Read ↗

Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic TransplantationSemantic proximity Read ↗

Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplantSemantic proximity Read ↗

Abatacept-based Graft-Versus-Host-Disease Prophylaxis in Haplo-identical Hematopoietic Cell Transplant: Single Center Experience in a High-Risk CohortSemantic proximity Read ↗

Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxisSemantic proximity Read ↗

A decade of experience using ATG and PTCy for graft‐versus‐host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.